Close Menu

NEW YORK (GenomeWeb) – Akonni Biosystems announced today that it has received a $300,000 grant from the National Institutes of Health to finalize development of a rapid, point-of-care tuberculosis assay for use on the company's TruDx 3000 sample-to-answer diagnostic system.

The grant was awarded under the NIH's Commercialization Readiness Pilot program, which is designed to help small businesses transition projects previously funded by the agency into the commercialization stage.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A bipartisan group of senators has introduced a bill seeking increased funding for certain fields, including synthetic biology, ScienceInsider reports. 

The Los Angeles Times reports that a case of the novel coronavirus making people ill in China has been reported in the US. 

Discover magazine writes that paleoproteomics is increasing being used in archaeology, paleoanthropology, and paleontology, including a recent study of a 6,000-year-old ring. 

In Nucleic Acids Research this week: mutagenic effects of ultraviolet "A" light, post-transcription effects of synonymous mutations, and more.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.

Feb
20
Sponsored by
Thermo Fisher Scientific

This webinar will discuss the use of 3’ mRNA sequencing to reduce the cost of gene expression studies on Illumina NGS systems.

Feb
26
Sponsored by
Autogen

This webinar will explain how the Clinic for Special Children in Strasburg, Pennsylvania, has transformed its DNA workflows to improve the diagnosis and treatment of genetic illnesses that are prevalent in the pediatric population of its community.